Biochronomer" technology and the development of aPF530, a sustained release formulation of granisetron

Journal of Experimental Pharmacology

Volumn 6, Issue , 2014, Pages 15-21

  Ottoboni, Thomas ^a   Gelder, Mark S ^a   O'Boyle, Erin ^b  

^a Imaging Therapeutics Inc   (United States)

^b FIBROGEN INC   (United States)

Author keywords

APF530; Formulation; Granisetron; Poly(orthoester); Sustained release

Indexed keywords

GRANISETRON; PALONOSETRON;

AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COMPARATIVE STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY DEVICE; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG SAFETY; HALF LIFE TIME; HUMAN; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; RANDOMIZED CONTROLLED TRIAL; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 85000163465     PISSN: None     EISSN: 11791454     Source Type: Journal    
DOI: 10.2147/JEP.S68880     Document Type: Article

References (23)

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Antiemesis - v1.2014. Fort Washington, PA: National Comprehensive Cancer Network; 2013. Available from: http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf. Accessed September 4, 2014.
2. Roila F, Herrstedt J, Aapro M., et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010; 21(SUPPL. 5):v232-v243.
3. Grunberg SM, Osoba D, Hesketh P.J., et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer. 2005; 13(2):80-84.
4. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004; 100(10):2261-2268.
5. Basch E, Prestrud AA, Hesketh P.J., et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189-4198.
6. Aapro M, Johnson J. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours. Gerontology. 2005; 51(5):287-296.
7. Kytril® (granisetron hydrochloride) tablets oral solution [prescribing information]. Basel: Hoffman-La Roche Ltd; 2010.
8. Kytril® (granisetron hydrochloride) injection [prescribing information]. South San Francisco, CA: Genentech, Inc.; 2011.
9. Stoltz R, Cyong JC, Shah A, Parisi S. Pharmacokinetic and safety evaluation of palonosetron, a 5-hydroxytryptamine-3 receptor antagonist, in US and Japanese healthy subjects. J Clin Pharmacol. 2004; 44(5): 520-531.
10. Saito M, Aogi K, Sekine I., et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative Phase III trial. Lancet Oncol. 2009; 10(2): 115-124.
11. Aloxi® (palonosetron HCl) injection for intravenous use [prescribing information]. Woodcliff Lake, NJ: Eisai Inc.; 2014.
12. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med. 2000; 342(21):1554-1559.
13. Heller J, Barr J. Biochronomer technology. Expert Opin Drug Deliv. 2005; 2(1):169-183.
14. Aapro M. Granisetron: an update on its clinical use in the management of nausea and vomiting. Oncologist. 2004; 9(6):673-686.
15. Hsu ES. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Am J Ther. 2010; 17(5):476-486.
16. Gabrail N, Yanagihara RH, Cooper W, et al. Pharmacokinetics (PK), tolerability, and efficacy of APF530 in patients receiving moderately (MEC) and highly (HEC) emetogenic chemotherapy: Phase II trial results [abstract]. J Clin Oncol. 2013; 31 Suppl: abstract e20518.
17. Raftopoulos H, Cooper W, O'Boyle E, Gabrail N, Boccia R., Gralla RJ. Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, double-blind, noninferior-ity phase 3 trial. Support Care Cancer. Epub 2014 September 2.
18. Hesketh PJ. Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. Oncologist. 1999; 4(3):191-196.
19. Hochberg J. A sharper Bonferroni procedure for multiple tests of significance. Biometrika. 1988; 75(4):800-802.
20. Charu V, Clark-Snow R, Gabrail N., et al. Patient satisfaction with control of emesis following chemotherapy [abstract]. Support Care Cancer. 2012; 20(Suppl 1):abstract 1109.
21. Mason JW, Moon TE, O'Boyle E, Dietz A. A randomized, placebo-controlled, four-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron, and moxifoxacin on QTc prolongation. Cancer Manag Res. 2014; 6:181-190.
22. Raftopoulos H, O'Boyle E, Gralla RJ, Rosenberg M, Barr J. The effect of continuous exposure to serotonin receptor antagonism on delayed emesis: an analysis of 1,535 patients in two randomized clinical trials with granisetron (G), APF530, and palonosetron (palo) [abstract]. J Clin Oncol. 2012; 30 Suppl: abstract e19635.
23. Botrel TE, Clark OA, Clark L, Paladini L., Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support Care Cancer. 2011; 19(6):823-832.